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Lax S, Rayes J, Wichaiyo S, Haining EJ, Lowe K, Grygielska B,
Laloo R, Flodby P, Borok Z, Crandall ED, Thickett DR, Watson
SP. Platelet receptor C-type lectin-like 2 (CLEC-2) protects against
lung injury via effects of its ligand podoplanin on inflammatory
alveolar macrophages in the mouse. Am J Physiol Lung Cell Mol
Physiol 313: L1016–L1029, 2017. First published August 24, 2017;
doi:10.1152/ajplung.00023.2017.—There is no therapeutic interven-
tion proven to prevent acute respiratory distress syndrome (ARDS).
Novel mechanistic insights into the pathophysiology of ARDS are
therefore required. Platelets are implicated in regulating many of the
pathogenic processes that occur during ARDS; however, the mecha-
nisms remain elusive. The platelet receptor CLEC-2 has been shown
to regulate vascular integrity at sites of acute inflammation. Therefore
the purpose of this study was to establish the role of CLEC-2 and its
ligand podoplanin in a mouse model of ARDS. Platelet-specific
CLEC-2-deficient, as well as alveolar epithelial type I cell (AECI)-
specific or hematopoietic-specific podoplanin deficient, mice were
established using cre-loxP strategies. Combining these with intratra-
cheal (IT) instillations of lipopolysaccharide (LPS), we demonstrate
that arterial oxygen saturation decline in response to IT-LPS in
platelet-specific CLEC-2-deficient mice is significantly augmented.
An increase in bronchoalveolar lavage (BAL) neutrophils and protein
was also observed 48 h post-IT-LPS, with significant increases in
pro-inflammatory chemokines detected in BAL of platelet-specific
CLEC-2-deficient animals. Deletion of podoplanin from hematopoi-
etic cells but not AECIs also reduces lung function and increases
pro-inflammatory chemokine expression following IT-LPS. Further-
more, we demonstrate that following IT-LPS, platelets are present in
BAL in aggregates with neutrophils, which allows for CLEC-2 inter-
action with podoplanin expressed on BAL inflammatory alveolar
macrophages. Taken together, these data suggest that the platelet
CLEC-2-podoplanin signaling axis regulates the severity of lung
inflammation in mice and is a possible novel target for therapeutic
intervention in patients at risk of developing ARDS.
acute respiratory distress syndrome; platelets; alveolar macrophages;
mouse models
INTRODUCTION
Acute respiratory distress syndrome (ARDS) is a devastating
clinical syndrome of acute respiratory failure in the critically
ill. It is the final common pathway of response to a variety of
direct pulmonary insults such as bacterial/viral pneumonia and
gastric aspiration, or indirect insults such as abdominal sepsis or
battlefield trauma (10, 35, 45). Under the Berlin definition for
ARDS, onset of diagnosis must be within 7 days, with bilateral
opacities present on chest X-ray and severity defined as “mild”
(PaO2/FIO2 200–300), “moderate” (PaO2/FIO2 100–200), or
“severe” (PaO2/FIO2 100) (10, 53). The incidence of ARDS has
been reported to range from 7.2 to 78.9 cases per 100,000
worldwide, with mortality estimated at ~40% and pulmonary
impairment persisting in up to 50% of survivors, leading to
enormous social and fiscal cost (45, 49, 55). There are no current
readily available tests that can clearly identify those who are at
high risk of ARDS, and no therapeutic interventions proven to
prevent its occurrence. Clearly other mechanistic insights into the
pathophysiology of ARDS are needed to identify new pathways
for therapeutic manipulation.
Traditionally thought of as key regulators of physiological
and pathogenic hemostasis, platelets are now recognized as
essential mediators of both innate and adaptive immunity
(22–24, 52). Platelets are implicated in regulating many of the
pathogenic processes that occur during ARDS, including neu-
trophil recruitment, macrophage-dependent inflammation, and
alveolar-capillary permeability through complex mechanisms
(37). Murine models suggest that thrombocytopenia is protec-
tive during sterile lipopolysaccharide (LPS)-induced lung in-
flammation, primarily by reducing neutrophil recruitment (16,
30). However, this would presumably be detrimental if the
bactericidal activities of neutrophils are required. Indeed,
thrombocytopenia in intensive care unit patients is associated
with an increased risk of ARDS (56). In addition, severe
thrombocytopenia (5  109 platelets/l) in a mouse model of
pneumonia-induced sepsis enhanced pro-inflammatory cyto-
kine release and significantly impaired survival (5).
Platelets are required to maintain endothelial barrier function
under both homeostatic and inflammatory conditions. Looney
et al. (30) originally demonstrated a pathogenic role for plate-
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lets in an anti-MHC I and LPS-induced murine transfusion-
related acute lung injury (TRALI) model. A more recent
publication, however, questioned the role of platelets in the
initiation and development stages of the TRALI model, with
only red blood cell accumulation/alveolar hemorrhage argued
to be platelet-dependent because of their role in regulating
vascular integrity (19). Maintenance of vascular integrity is
primarily driven via activation of and signaling through the
immunoreceptor tyrosine-based activation motif (ITAM)-con-
taining receptors (29). Murine platelets express two ITAMs:
GPVI and the hemITAM C-type lectin-like 2 (CLEC-2), both
of which are critical for securing vascular integrity within the
lungs during inflammation (2). Whereas GPVI is restricted to
platelets, CLEC-2 expression has been shown to be present at
a low level on a small subset of inflammatory cells (33, 39). To
date, the only known endogenous ligand for CLEC-2 is podo-
planin (also known as gp38 or T1), a cell surface protein
originally described on kidney podocytes and alveolar epithe-
lial type I cells (AECIs) (3, 51) that is also expressed on
lymphatic endothelial cells (43), inflammatory macrophages
(26), CD4 T cell subsets (48), and stromal cells (11). Mice
deficient in either CLEC-2 or podoplanin exhibit separation
defects of the blood and lymphatic systems, and present with
significantly altered lung function that may contribute to their
perinatal lethality (12, 50). Furthermore, platelet activation via
CLEC-2 is independent of major hemostatic pathways and thus
is a candidate for the development of novel therapies in lung
injury (40).
On the basis of the expression of podoplanin in the lung, the
unusual role of CLEC-2 in platelet activation and the pheno-
type of CLEC-2 or podoplanin-deficient mice, we hypothe-
sized that the CLEC-2-podoplanin axis may play an as yet
unrealized role in ARDS. In this study we investigate the in
vivo consequences on acute lung injury of deleting CLEC-2 or
podoplanin by using a mouse model of ARDS. We show that
LPS-induced lung inflammation leads to recruitment of plate-
lets predominantly bound to neutrophils into alveoli. Further-
more, CLEC-2 expressed on platelets is required to limit lung
function decline as assessed by arterial oxygen saturation,
confirmed by increases in neutrophilia and BAL protein ob-
served in CLEC-2 deficient animals. We further demonstrate
that this action is mediated by interaction of CLEC-2 with its
ligand podoplanin expressed on a macrophage population
(CD11bCD11cF4/80) only present in alveoli during in-
flammatory conditions. Taken together, these data suggest that
the platelet CLEC-2-podoplanin signaling axis is protective
during a model of mouse lung injury, and is therefore a
possible novel target for future therapeutic intervention in
patients at risk of developing ARDS.
MATERIALS AND METHODS
Mice. All mice were maintained in individually ventilated cages
under a 12-h:12-h light/dark cycle at a constant temperature of 20°C
with food and water given ad libitum at the Biomedical Services Unit,
Birmingham University, UK. All experiments were performed in
accordance with UK laws [Animal (Scientific Procedures) Act 1986]
with approval of local ethics committee and UK Home Office ap-
proval under PPL 40/3741. Clec2fl/fl mice with either PF4cre, Rosa26-
ERT2cre (ERT2cre), or CD11c-cre along with Pdpnfl/fl VAV1cre
have been described previously (1, 12, 20, 33). Animals were fed with
FormulaLab Diet 5008 (Laboratory-Diet, St. Louis, MO). When
required, 4- to 6-wk-old Clec2fl/flERT2cre and their Clec2fl/fl control
littermates were fed for 2 wk with tamoxifen-supplemented diet TAM
400 (Envigo, UK), and then returned to the FormulaLab Diet 5008
chow. Mice expressing Aquaporin 5 cre (Aqp5cre) (13) were crossed
with mice expressing the podoplanin floxed allele to generate the
Pdpnfl/flAqp5cre strain. Wild-type C57Bl/6 mice were purchased
from Harlan Laboratories (Oxford, UK). Male mice, aged 9–16 wk,
were used.
Intratracheal LPS model. Instillations of 40 g LPS (Escherichia
coli O111:B4, InvivoGen, France) in a 50-l bolus of phosphate-
buffered saline (PBS) or PBS alone were administered to each mouse.
Mice were euthnaized at 48 h post-LPS instillation (peak of cellular
recruitment), or following resolution of the inflammatory response, 9
days post-LPS instillation (28). Infrared pulse oximetry and pulse
distention were assessed by MouseOx Plus (Starr Life Sciences) and
bronchoalveolar lavage (BAL) collected as previously described (28).
The epithelial damage marker receptor for advanced glycation end
products (RAGE), as well as cytokine and chemokine levels were
analyzed using Fluorokine MAP Multiplex (R&D Systems, UK).
Whole blood was collected into ethylenediaminetetraacetic acid
(EDTA), analyzed on an ABX Pentra 60 (Horbia, UK), and plasma
was isolated by centrifugation at 2,000 g for 30 min.
Lung water and protein permeability. Protein permeability was
calculated by measuring the concentration of total protein in BAL
samples per milliliter of fluid recovered. To calculate wet wt-to-dry wt
ratio, mice were culled by cervical dislocation and lungs removed en
bloc. Heart, thymus, and connective tissue were removed, and “wet”
lungs weighed. Lungs were dried in a 55°C oven for 48 h. The
resulting “dry” lungs were weighed, and the ratio between the two
values determined.
Platelet depletion. Intraperitoneal injections of 1.5 g/g anti-mouse
GP1b antibody (EMFRET analytics, Germany; R300) were given
18 h before IT-LPS. Complete and sustained platelet depletion was
confirmed in whole blood immediately before IT-LPS; 25 10 
103/mm3 compared with 959 34  103/mm3 isotype controls
(~97%).
Platelet transfusion. Blood was collected from the inferior vena
cava of wild-type C57Bl/6 mice under terminal anesthesia, and
platelets were prepared as previously described (46). Blood was
pooled from a number of donor mice, transfused into recipient
Clec2fl/fl or Clec2fl/flERT2cre mice (2  108 in 200 l of buffer via
the tail vein). Immediately after intravenous injections, recipient mice
were subjected to IT-LPS. The platelets to be transfused were con-
firmed to be inactive, with the potential to become fully activated by
analyzing P-selectin and fibrinogen binding via flow cytometry fol-
lowing incubation with or without 0.5 U/ml thrombin (Sigma-Aldrich,
UK) for 15 min at room temperature.
Lung digestion and flow cytometry. Lungs were perfused with 10
ml of 200 nM EDTA/PBS until white. BAL was extracted and the left
lobe digested using Liberase TL (0.4 Wunsch units/ml; Roche) with
DNase (50 g/ml; Roche) and incubated at 37°C in a rotating shaker
(200 rpm) for 40 min. Single-cell suspensions were ensured by
passing through a 25-G needle four times and washing the cells
through a 70-m filter. Pelleted cells from BAL were first enumerated
and then assessed by flow cytometry alongside lung tissue cells by
using fluorophore-conjugated antibodies (eBioscience). Only SyTOX
(Invitrogen) negative cells (live cells) from digested tissue were
analyzed. BAL neutrophil and red blood cell numbers are presented
per milliliter of BAL. Cell populations from digested tissue were
stained as previously described (18) or as stated in the text.
Lung histology and podoplanin expression. Lungs were inflated
postmortem with 1.5 ml of a solution containing optimum cutting
temperature compound (Tissue-Tek, The Netherlands) in PBS (1:2)
introduced via the trachea by using a 19-G needle. The trachea was
then sutured and lungs removed en bloc, frozen over dry ice, and
stored at 	80°C. Frozen sections of 20 m were processed for
hematoxylin and eosin or podoplanin staining (clone 8.1.1., eBiosci-
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ence). Syrian hamster IgG controls were used to confirm specific
staining (data not shown). Images were analyzed using a Zeiss Axio
Scan.Z1 microscope and ZEN software.
Statistical analysis. All parameters were analyzed using Prism 6
(GraphPad Software). Significance was assessed by ANOVA with
relevant posttest analysis as indicated in the text. Data are presented
as Box-Whisker plots with mean displayed and the range of minimum
to maximum data points.
RESULTS
Intratracheal LPS induces recruitment of platelet-neutrophil
aggregates into lung alveoli. When assessed by flow cytometry,
BAL from unchallenged mice contains predominantly alveolar
macrophages (CD11b	CD11cF4/80). As expected, following
IT-LPS the percentage of neutrophils (CD11bCD11c	Gr1)
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increases dramatically in BAL, along with an inflammatory mac-
rophage population (CD11bCD11cF4/80) (Fig. 1, A and B).
As a consequence resident alveolar macrophages are reduced in
percentage. When enumerated, the numbers of tissue resident
alveolar macrophages remain constant, with increases in neutro-
phils and inflammatory alveolar macrophages observed (Fig. 1C).
Total BAL protein and lung wet wt-to-dry wt ratio confirms that
IT-LPS induces significant lung damage compared with PBS-
treated or unchallenged controls (Fig. 1D). No significant differ-
ences are observed between unchallenged and IT-PBS treated
mice.
The critical role of platelets during LPS-induced lung injury
has previously been demonstrated in platelet-depleted mice by
using administration of a rat anti-mouse GP1b monoclonal
antibody (7, 15). In our model we confirm these data and
observe that pretreatment of wild-type mice with anti-GP1b
antibody significantly increases bleeding into the alveoli, as
assessed by red blood cell (RBC) accumulation in BAL com-
pared with isotype-treated controls following IT-LPS (53.9
fold; Fig. 1, E and F). Concomitantly, the number of neutro-
phils observed in BAL is significantly reduced in platelet-
depleted animals following IT-LPS (4.5 fold; Fig. 1G). As a
consequence, anti-GP1b-treated mice present with an irregu-
lar breathing pattern and reduced activity 6 h after LPS admin-
istration compared with isotype-treated controls. One anti-
GP1b antibody-treated animal had to be culled 4 h post-IT-
LPS because of welfare concerns (* in Fig. 1E). This animal
was excluded from analysis.
In wild-type mice with normal platelet counts, IT-PBS
induces a decrease in platelet count by 17% compared with
unchallenged controls. Platelet count drops 13% further fol-
lowing IT-LPS (Fig. 1G), coinciding with the emergence of a
CD41 platelet population within the BAL, not seen in control
or IT-PBS-treated BAL (Fig. 1, H and I). Flow cytometry
reveals that the majority of these platelets are within platelet-
leucocyte aggregates (PLAs; 80.8  5.3%), primarily bound to
Gr-1 neutrophils (58.3  5.8%) (Fig. 1J). These data dem-
onstrate the location of a population of platelets, which express
CLEC-2, within the alveoli during IT-LPS-induced inflamma-
tion.
Fig. 1. Platelets are present in bronchoalveolar lavage (BAL) during a mouse model of acute respiratory distress syndrome (ARDS). Unchallenged BAL and BAL
isolated 48 h after intratracheal phosphate-buffered saline (IT-PBS) or lipopolysaccharide (LPS) were analyzed from wild-type (WT) mice by flow cytometry.
A: representative histograms for the identification of leucocyte (CD45) cell populations in mouse BAL before and 48 h after IT-PBS or LPS. [From Duan et
al. (9).] Podoplanin expression was analyzed by setting the gate at 1% by using a Syrian hamster IgG isotype. FS, forward scatter; SS, side scatter. The major
leucocyte populations observed in BAL displayed as percentage of total CD45 BAL cells (B) and absolute cell counts (C); n  8. D: alveolar-capillary damage
assessed in unchallenged mice and 48 h after IT-PBS or LPS; n 6–8. E: BAL from WT mice pretreated with isotype (control) or anti-GP1b antibody (platelet
depleted) mice 6 h after IT-LPS; *excluded animal. F: the numbers of red blood cells (RBCs) and neutrophils in BAL of WT mice pretreated with isotype
(control) or anti-GP1b antibody (platelet depleted) mice 6 h after IT-LPS. Isotype control n 6, anti-GP1b n 5; Student’s t-test. G: systemic platelet counts
from WT mice where analyzed in whole blood on an ABX Pentra 60 (Horbia) in unchallenged mice or 48 h after IT-PBS or LPS; n  8. H: representative
histograms for the identification of CD41 platelets in BAL and characterization of platelet-leucocyte aggregates (PLA) following IT-LPS. I: CD41 platelets
observed in BAL in WT mice 48 h following IT-LPS. UC, unchallenged. J: identification of CD41CD45 PLAs in BAL 48 h following IT-LPS; n  8.
One-way ANOVA performed with Tukey’s multiple comparison posttests; *P  0.05, **P  0.01, and ***P  0.001.
Fig. 2. Two-week tamoxifen-induced deletion of
C-type lectin-like 2 (CLEC-2) on platelets. A:
representative histograms using 17D9-FITC to
detect CLEC-2 expression on platelets in whole
blood analyzed 1 wk after starting tamoxifen diet
(tam) and after 2-wk tamoxifen diet followed by 5
wk of normal diet in Clec2fl/flERT2cre mice com-
pared with floxed only controls. An IgG2b-FITC
isotype control was also included. B: percentage
of CLEC-2 expression in CD41 positive platelets
was analyzed by flow cytometry. One-way
ANOVA with Tukey’s multiple posttests; n  4;
***P  0.001.
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Platelet-expressed CLEC-2 protects against LPS-induced
lung injury. Constitutive deletion of CLEC-2 is perinatally
lethal (12). Therefore, we used two cre-loxP strategies to
specifically delete CLEC-2 from platelets in mice. First a
rosa26-driven tamoxifen-inducible (ERT2) cre was used. When
a tamoxifen diet is given for only 2 wk, recombination in the
megakaryocyte lineage allows for newly synthesized “knock-
out” platelets to be produced because of their relatively short
circulation time of 5 days (33) (Fig. 2). This is followed by a
4–5 wk “washout” period of normal diet to ensure the anti-
Fig. 3. Effect of CLEC-2 deletion in platelets dur-
ing a mouse model of ARDS. Arterial oxygen
saturation analyzed by noninvasive pulse oximetry
following IT-LPS in tamoxifen (ERT2)cre- or
PF4cre-induced CLEC-2-deficient mice compared
with cre negative controls (A and B, respectively).
Tamoxifen-treated Clec2fl/fl vs. Clec2fl/flERT2cre
P  0.001; Clec2fl/fl vs. Clec2fl/flPF4cre; P 
0.001. C: pulse distention analyzed by MouseOx
Plus following IT-LPS in tamoxifen (ERT2)- or
PF4cre-induced CLEC-2-deficient mice compared
with cre negative controls. Tamoxifen-treated
Clec2fl/fl: n  8; Clec2fl/flERT2cre: n  7; Clec2fl/fl:
n  8; Clec2fl/flPF4cre: n  8; means SE. Two-
way ANOVA performed with Tukey’s multiple
comparisons test. D: representative images of lung
sections stained for hematoxylin and eosin in un-
challenged and 48 h after IT-LPS-treated ERT2cre-
or PF4cre-induced CLEC-2-deficient mice com-
pared with cre negative controls. Alveolar and
interstitial neutrophils are highlighted by arrows
and arrowheads, respectively. Scale bar: 100 m;
n  3–5. E: neutrophil recruitment and pulmonary
endothelial and epithelial damage parameters in
unchallenged and IT-LPS-treated ERT2cre- or
PF4cre-induced CLEC-2-deficient mice compared
with cre negative controls; n  7–13. PF4cre only,
n  4; Clec2fl/flCD11c-cre, n  8. F and G:
bronchoalveolar lavage (BAL) cyto- and chemo-
kine levels in unchallenged and IT-LPS-treated
ERT2cre- or PF4cre-induced CLEC-2-deficient
mice compared with cre negative controls; n  6.
H: systemic platelet, white blood cell (WBC), and
red blood cell (RBC) counts were analyzed in
whole blood on an ABX Pentra 60 (Horbia); n 
6–11. One-way ANOVA performed with Tukey’s
multiple comparison posttests; *P  0.05, **P 
0.01, and ***P  0.001. UC, unchallenged;
N.D., not detected; 48 h  48 h post-IT-LPS.
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inflammatory effects of tamoxifen do not alter responses to
LPS. A PF4cre was used to delete CLEC-2 specifically in the
megakaryocyte/platelet lineage (12).
To investigate the consequence of platelet-CLEC-2 deletion,
we first analyzed arterial oxygen saturation (SaO2) via pulse
oximetry to assess overall lung function. Instillation of PBS in
CLEC-2-deficient animals or littermate controls does not alter
SaO2, which is maintained at ~96% (data not shown). After
IT-LPS, deletion of CLEC-2 significantly reduces SaO2 in both
genetically altered strains compared with floxed controls (P 
0.001; Fig. 3, A and B). There is no significant difference
between the CLEC-2-deficient strains (P  0.34) or between
floxed-only controls given a normal or tamoxifen diet (P 
0.54). In addition, there are no significant differences in pulse
distention, indicative of blood flow (41), between these strains
(Fig. 3C).
Immunohistochemistry demonstrates an increase in accumu-
lation of both alveolar and interstitial neutrophils in CLEC-2-
deficient animals 48 h post-IT-LPS compared with littermate
controls (Fig. 3D, arrowheads and arrows, respectively). To
quantify this, we analyzed BAL neutrophil counts. A signifi-
cant increase in alveolar neutrophilia 48 h post-IT-LPS in both
models of CLEC-2-deficient mice was observed compared
with littermate controls (2.3–2.9 fold; Fig. 3E). In addition,
quantification of interstitial neutrophilia suggests that CLEC-2
deletion driven by PF4cre leads to an increase in the number of
neutrophils within lung tissue (Fig. 3E).
A significant increase in BAL protein is observed in both
CLEC-2-deficient strains compared with controls 48 h post-
IT-LPS (1.5–1.7 fold; Fig. 3E). However, no significant dif-
ferences are observed in wet wt-to-dry wt ratio, expression of
the epithelial cell damage marker, RAGE, or RBC accumula-
Fig. 4. Effect of platelet transfusion during a mouse model of ARDS. A: purity and CLEC-2 expression and activity were confirmed in platelets prepared from
WT mice. These platelets were given via intravenous injection (2  108 per mouse) immediately before LPS instillations into CLEC-2 sufficient (Clec2fl/fl) and
platelet-specific CLEC-2-deficient (Clec2fl/flERT2cre) mice. Control and CLEC-2-sufficient mice that were given IT-LPS on the same day but did not receive
platelets were also included. B: total weight loss along with systemic white blood cell (WBC), red blood cell (RBC), and platelet counts in whole blood were
analyzed 48 h post-IT-LPS. C: bronchoalveolar (BAL) neutrophilia and total BAL protein were also analyzed 48 h post-IT-LPS. One-way ANOVA performed
with Tukey’s multiple comparison posttests; Clec2fl/fl (no transfusion) n  4, Clec2fl/fl  platelets n  5, Clec2fl/flERT2cre platelets n  7; *P  0.05 and
**P  0.01; n.s.  not significant.
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tion in BAL (alveolar hemorrhage) 48 h post-IT-LPS in CLEC-
2-deficient strains compared with controls (Fig. 3E). These
data suggest that the increases in BAL protein observed may
reflect the increase in protein derived from inflammatory cells
rather than an increase in lung permeability in CLEC-2-defi-
cient animals (36).
When using cre-loxP technology, nonspecific endonuclease
activity of the cre recombinase is always a concern (31).
However, we observe no cre-related effects on neutrophil
recruitment or BAL protein using PF4cre only expressing mice
48 h post-IT-LPS (Fig. 3E, striped plots). This suggests our
data are specific to CLEC-2 deletion. Furthermore, as a cell
type previously reported to express CLEC-2 and to have a
significant role during inflammation, we used the previously
characterized Clec2fl/flCD11c-cre mice to assess the contribu-
tion of CLEC-2 expressed on dendritic cells (1). We again
observe no effects on neutrophil recruitment or BAL protein
using the dendritic cell-specific CLEC-2-deficient mice (Fig.
3E, red plots).
Expression of the murine neutrophil recruitment chemo-
kines, keratinocyte-derived chemokine (KC) and macrophage
inflammatory protein 2 (MIP-2), in BAL are significantly
increased in CLEC-2-deficient animals (2.6–3.0 and 8.8–14.8
fold, respectively) (Fig. 3F). However, no significant differ-
ence was observed in expression of the monocyte recruitment
chemokine MCP-1 or pro-inflammatory cytokines, tumor ne-
crosis factor (TNF), and interleukin (IL)-6 (Fig. 3G). Platelet
numbers in whole blood from Clec2fl/flERT2cre mice, along
with white blood cell (WBC) and RBC counts of all cre mice,
were comparable to floxed-only controls (Fig. 3H). Clec2fl/fl
PF4cre mice have a mild reduction in platelet numbers
(~13–23%) due to blood-lymphatic mixing, but this does not
affect WBC or RBC, as previously reported (12). Together
these data suggest that platelet CLEC-2 is protective during
IT-LPS.
A recent publication utilizes a simple platelet transfusion to
confirm the role of platelet CLEC-2 during a mouse model of
deep vein thrombosis (DVT) (46). Therefore, using a similar
strategy we sought to confirm that the dysregulation of lung
inflammation in the CLEC-2-deficient strains is due to the lack
of CLEC-2 on platelets. Purity, CLEC-2 expression, and po-
tential activation of the purified wild-type platelets used in
these experiments were first confirmed by flow cytometry (Fig.
4A). Although simple in concept, platelet transfusion within an
inflammatory model such as IT-LPS, however, leads to a
complex phenotype. Platelet transfusion immediately before
IT-LPS into CLEC-2-deficient or sufficient controls has a
negative impact on animal welfare, as evidenced by a signifi-
cant decrease in total body weight loss and a pronounced
systemic leukopenia 48 h post-IT-LPS compared with mice
that did not receive a transfusion (Fig. 4B). Transfusions did
not alter systemic numbers of RBCs or platelets in whole blood
48 h after IT-LPS.
In wild-type Clec2fl/fl controls, platelet transfusion signifi-
cantly increases neutrophil recruitment to the alveoli along
with a significant increase in total BAL protein 48 h post-IT-
LPS compared with mice that did not receive platelets (Fig.
4C). When platelet transfusions were given to platelet-specific
CLEC-2-deficient animals (Clec2fl/flERT2cre), although a
trend for reduced neutrophilia was observed following IT-LPS,
their response was not significantly different to Clec2fl/fl mice
that also received platelets (Fig. 4C, gray plots). In addition, no
difference in total BAL protein was observed comparing
Clec2fl/fl and Clec2fl/flERT2cre animals that had all received
platelets.
The altered response observed in the control mice that
received platelets makes subsequent analysis of CLEC-2-defi-
cient animals problematic. Having observed that without plate-
let transfusion, CLEC-2-deficient mice have increased BAL
neutrophilia and protein, one may assume that this would also
be upheld following the addition of a platelet transfusion. The
fact that we do not observe any additive effects of lacking
platelet CLEC-2 in mice that receive CLEC-2-expressing
platelets may suggest that the platelet transfusion has indeed
“rescued” the defect in deficient mice. This supports our
findings that it is CLEC-2, specifically expressed on platelets,
Table 1. Phenotype of Pdpnfl/flAqp5cre and Pdpnfl/flVAV1cre mouse strains
Parameter Pdpnfl/fl Pdpnfl/flAqp5cre Pdpnfl/flVAV1cre P
Body weight, g 28.8  1.7 27.8 0.7 27.1  2.8 0.338
Normalized organ weight
Lungs 11.5  1.0 11.2 0.4 11.5  0.7 0.740
Heart 5.6  0.4 5.5 0.5 5.4  0.4 0.829
Spleen 2.9  0.4 3.0 0.2 2.7  0.2 0.206
Thymus 1.8  0.3 2.0 0.2 1.9  0.5 0.787
Systemic platelet count, 103/mm3 858  82 822 87 847  66 0.700
CLEC-2 expression on platelets, % 99.1  0.5 99.0  0.7 98.7  0.8 0.599
n 6 6 6
Values are means SD with one-way ANOVA. Male mice 10.5–12 wk old were analyzed and compared with Pdpnfl/fl littermate controls. Organ weights were
normalized to body weight.




Total Expected Observed PPdpn Cre
Pdpnfl/fl X Pdpnfl/flAqp5cre 109
M fl/fl — 27.25 22 0.162
M fl/fl Aqp5 27.25 32
F fl/fl — 27.25 25 0.579
F fl/fl Aqp5 27.25 29
Pdpnfl/fl X Pdpnfl/flVAV1cre 247
M fl/fl — 61.75 67 0.173
M fl/fl VAV1 61.75 53
F fl/fl — 61.75 63 0.747
F fl/fl VAV1 61.75 64
No significant differences in terms of inheritance in either strain or within
sexes were detected by 
2-test.
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that is required to limit pulmonary inflammation during IT-
LPS. However, this explanation may be too simplistic, with the
possibility that platelet transfusion alters and/or overcomes any
CLEC-2-dependent signaling.
Podoplanin expression in Aqp5cre and VAV1cre conditional
knockout lungs. The only known endogenous ligand for
CLEC-2 is podoplanin. Like CLEC-2, constitutive deletion
of podoplanin is lethal in murine models (50). Therefore we
generated two conditional knockout strains by using a floxed
podoplanin allele [Pdpnfl/fl (32)]. We first used previously
characterized Aqp5cre mice (13) to generate a novel AECI-
specific podoplanin-deficient strain. In addition, we used the
Vav1cre strain to generate hematopoietic-specific podopla-
nin-deficient mice (20). Both strains are viable, without any
overt phenotype (Table 1) and exhibit Mendelian inheri-
tance (Table 2).
To characterize these novel mouse models, we first used
immunohistochemistry to evaluate podoplanin expression in
unchallenged and IT-LPS-treated lungs. Deletion of podopla-
nin is observed only in the Pdpnfl/flAqp5cre lungs (Fig. 5A).
To quantify podoplanin deletion in specific cell populations,
lung tissue from unchallenged and IT-LPS-treated mice was
perfused, lavage fluid isolated, and tissue enzymatically di-
gested. Each cell population was analyzed by flow cytometry
using the gating strategy shown in Fig. 6 and as previously
reported (18). In digested lung tissue from unchallenged (UC)
mice, we first confirmed that podoplanin in controls is ex-
pressed on AECI, lymphatic endothelial cells (LECs), fibro-
blasts, tissue resident macrophages, dendritic cells (DCs), and
CD4 T cells (Fig. 5B, UC white plots). Furthermore, LPS-
induced lung injury significantly increases podoplanin expres-
sion on the leucocyte populations (Fig. 5B, 48-h white plots).
Fig. 5. Podoplanin expression in unchallenged and IT-LPS-treated Pdpnfl/fl Aqp5cre and VAV1cre mice. A: representative images of lung sections stained
using 8.1.1 to detect podoplanin (brown) and hematoxylin (blue) in unchallenged and 48 h after IT-LPS-treated Aqp5cre- or VAV1cre-induced
podoplanin-deficient mice compared with cre negative controls. Scale bar  100 m; n  4. B: flow cytometry analysis of podoplanin-expressing cell
populations isolated from perfused lung tissue following enzymatic digestion; n  7–14. C: flow cytometry analysis of podoplanin expression in alveolar
macrophage subpopulations isolated from bronchoalveolar lavage (BAL); n  7–14. One-way ANOVA performed with Tukey’s multiple comparison
posttests; *P  0.05, **P  0.01, and ***P  0.001. UC, unchallenged; EpCAM, epithelial cell adhesion molecule; LECs, lymphatic endothelial cells;
DCs, dendritic cells; AM, alveolar macrophage.
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As expected, the Aqp5cre efficiently reduces podoplanin
expression on AECIs (94.2  0.8 to 7.5  0.4%), which is
maintained following LPS-induced inflammation (Fig. 5B,
gray plots). Pdpnfl/flAqp5cre mice also have a significant
reduction in podoplanin expression on LECs (83.9  2.5 to
10.2  0.5%) and tissue resident macrophages (34.1  5.2 to
8.9  2.8%). Podoplanin expression remains significantly re-
duced in these cell populations following IT-LPS. In contrast,
expression of podoplanin is maintained in all lung cell popu-
lations analyzed in unchallenged Pdpnfl/flVAV1cre lungs
(Fig. 5B, UC black plots). However, inflammation-induced
increases in podoplanin expression are inhibited in lung leu-
cocyte populations.
The two macrophage populations present in BAL (identified
in Fig. 1A) were also analyzed for podoplanin expression.
Podoplanin is expressed at a very low level in alveolar mac-
rophages, which does not change following IT-LPS (Fig. 5C,
white plots). In addition, there are no significant differences in
expression in both conditional podoplanin knockout strains (Fig.
5C, gray and black plots). This is in contrast to BAL inflammatory
alveolar macrophages, which express a moderate level of podo-
planin in controls (29.3% 3.8) and is significantly reduced only
in Pdpnfl/flVAV1cre animals (13.2% 2.2; Fig. 5C, black
plots).
Hematopoietic-expressed podoplanin protects against LPS-
induced lung injury. To investigate the consequence of podo-
planin deletion in our conditional strains, we first analyzed
SaO2following IT-LPS. Deletion of podoplanin significantly
reduced SaO2only in Pdpn
fl/flVAV1cre compared with con-
trols and Pdpnfl/flAqp5cre animals (P  0.001; Fig. 7A),
without altering blood flow (Fig. 7B). Immunohistochemis-
Fig. 6. Gating strategy used in digested lung
tissue. Representative histograms for the iden-
tification of podoplanin-expressing cell popu-
lations following Liberase/DNase digestion.
[From Hashimoto et al. (18).] Only alive (Sy-
TOX Red negative) cells were analyzed using
a stromal (A) or leucocyte (B) antibody panel
in perfused and digested mouse lungs. Podo-
planin expression was analyzed by setting the
gate at 1% by using a Syrian hamster IgG
isotype as shown. Blood endothelial cells
(BECs) are defined within the stromal gate as
EpCAM	CD31LYVE	.
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try analysis suggests that neutrophil recruitment following
IT-LPS is unaltered in both podoplanin-deficient strains
(Fig. 7C). This was supported by analysis of neutrophil
counts in BAL and lung tissue 48 h post-IT-LPS, which
confirmed that LPS-induced neutrophilia is not significantly
different in either strain (Fig. 7D). However, in line with
CLEC-2-deficient strains there is a significant increase in
BAL protein in Pdpnfl/flVAV1cre animals (1.6 fold; Fig.
7D). Again, this is independent of changes in wet wt-to-dry
wt ratio and epithelial cell damage as assessed by expression
of RAGE in BAL fluid (Fig. 7D). However, contrary to
CLEC-2-deficient strains, the number of RBCs in BAL is
significantly increased only in Pdpnfl/flVAV1cre post-IT-
LPS (Fig. 7D). Mice expressing VAV1cre-only did not
Fig. 7. Effect of podoplanin deletion from
Aqp5 or VAV1 cells on lung function in a
mouse model of ARDS. A: arterial oxygen
saturation analyzed by noninvasive pulse oxi-
metry following IT-LPS in Aqp5cre- or
VAV1cre-induced podoplanin-deficient mice
compared with cre negative controls (P 
0.001). B: pulse distention analyzed by
MouseOx Plus following IT-LPS in Aqp5cre-
or VAV1cre-induced podoplanin-deficient
mice compared with cre negative controls.
Pdpnfl/fl n  8, Pdpnfl/flAqp5cre n  7, Pd-
pnfl/flVAV1cre n  7; means SE. Two-
way ANOVA performed with Tukey’s mul-
tiple comparisons test; ***P  0.001. C:
representative images of lung sections
stained for hematoxylin and eosin in unchal-
lenged and 48 h after IT-LPS treatment in
Aqp5cre or VAV1cre-induced podoplanin-
deficient mice compared with cre negative
controls. Alveolar and interstitial neutrophils
are highlighted by arrows and arrowheads,
respectively. Scale bar  100 m; n  3. D:
neutrophil recruitment and pulmonary endo-
thelial and epithelial damage parameters in
unchallenged and IT-LPS-treated Aqp5cre-
or VAV1cre-induced podoplanin-deficient
mice compared with cre negative controls;
n  7–14. E and F: BAL cyto- and chemo-
kine levels in unchallenged and IT-LPS-
treated Aqp5cre- or VAV1cre-induced podo-
planin-deficient mice compared with cre neg-
ative controls; n  6. G: systemic platelet,
white blood cell (WBC), and red blood cell
counts (RBC) were analyzed in whole blood
on an ABX Pentra 60 (Horbia); n  6–11.
One-way ANOVA performed with Tukey’s
multiple comparison posttests; *P  0.05,
**P  0.01, and ***P  0.001. UC, unchal-
lenged; N.D., not detected; 48 h  48 h
post-IT-LPS.
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exhibit an increase in neutrophilia or BAL protein compared
with floxed-only controls 48 h post-IT-LPS, suggesting our
data are specific to podoplanin deletion (Fig. 7D, striped
plots).
Expression of the neutrophil recruitment chemokines KC and
MIP-2 are both significantly increased in Pdpnfl/flVAV1cre
BAL compared with floxed-only controls and Pdpnfl/flAqp5cre
animals, mirroring the CLEC-2-deficient strains (Fig. 7E). In
addition, no significant difference is observed in MCP-1, TNF,
or IL-6 levels in BAL (Fig. 7F). The increase in BAL RBCs is
mirrored by a decrease in platelet counts observed in Pdpnfl/fl
VAV1cre mice following IT-LPS, whereas WBC and RBC
counts are comparable to floxed-only controls (Fig. 7G).
DISCUSSION
The data presented in this study 1) confirm that platelets are
present in the alveolar space during inflammation, primarily in
aggregates with neutrophils; 2) show that CLEC-2 expressed
on platelets protects against excessive lung inflammation in a
mouse model of ARDS; 3) are suggestive of a nonessential, or
redundant, role for the CLEC-2 ligand, podoplanin, on AECI
and LECs during lung development and function during in-
flammation; and 4) implicate podoplanin expression on hema-
topoietic-derived cells in protecting against exaggerated lung
inflammation in a mouse model of ARDS.
Platelets have been implicated in regulating many processes
dysregulated during ARDS, including neutrophil recruitment,
macrophage-dependent inflammation, and alveolar-capillary
permeability; however, the mechanisms are incompletely un-
derstood (37, 52). Previously, Ortiz-Muñoz et al. (42) used
two-photon intravital microscopy to show neutrophil-platelet
aggregates forming dynamically during LPS-induced inflam-
mation, which migrate into the alveolar spaces. Here we first
confirm that there is an increase in platelets present within
alveoli following intratracheal LPS administration. In addition,
we confirm that these platelets are primarily bound to neutro-
phils in BAL fluid.
Having confirmed the presence of platelet-neutrophil aggre-
gates in the alveoli, we investigated the role of the platelet
receptor CLEC-2 in regulating lung inflammation. Using two
complementary strategies of CLEC-2 deletion, our data sug-
gest that platelet CLEC-2 is protective during LPS-induced
lung injury. Our results show for the first time that in a mouse
model of ARDS, expression of CLEC-2 on platelets limits
neutrophil extravasation into the alveolar spaces, possibly via
modulation of the chemokines KC and MIP-2, maintaining
lung function. In the lung, MIP-2 is primarily produced by
alveolar macrophages (8), whereas KC is expressed by epithe-
lial cells, neutrophils, and macrophages (21). Platelets also
contain KC (14), so whether CLEC-2 deficiency only affects
KC release from platelets or modulates expression of the
inflammatory chemokines by other cell types is the focus of
ongoing research.
This protective role for platelets in a mouse model of
intratracheal LPS-induced lung injury contradicts recent stud-
ies which demonstrate that reduced platelet number and/or
activation is protective during aerosolized LPS (16, 54), acid-
induced (58), and TRALI (30, 42) mouse models. In line with
these data a recent prospective study using a human model of
ARDS suggests that reduced platelet activation via aspirin
administration significantly reduces acute pulmonary neutro-
philia (17). However, meta-analysis of clinical studies using
aspirin in the management of ARDS concluded that data are
insufficient to justify the use of aspirin as yet (44). Interest-
ingly, an injurious role for platelet CLEC-2 during a mouse
model of deep vein thrombosis was recently reported (46), with
platelet transfusion shown to be protective in mice that were
first subjected to extracorporeal circulation (34) or during
mouse models of sepsis (57). Together with the data we present
here that suggests platelet transfusion before IT-LPS has a
detrimental effect, these data emphasize the possible model-
dependent and/or receptor-dependent effects of platelets during
inflammation.





















Inflammatory alveolar macrophage Monocyte
Fig. 8. Proposed model for the mechanism of CLEC-2
podoplanin-dependent regulation of acute lung injury.
During acute lung inflammation, the CXC chemokines
KC and MIP-2 are produced by alveolar macrophages
(AM) and epithelial cells (1). Platelets in aggregates
with neutrophils (N) are recruited into the alveoli (2).
At the same time, tissue resident AM and monocytes
(m) from the blood contribute to the appearance of
CD11b inflammatory AM (iAM) in the alveoli,
which express podoplanin (3). Together in the alveolar
space, CLEC-2 expressed on platelets interacts with
podoplanin on the iAMs regulating MMP-12 release
from iAMs (4). MMP-12 is able to cleave and inacti-
vate the CXC chemokines contributing to the “off”
signal during acute inflammation in the lung and lim-
iting lung injury.
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The only known endogenous ligand for CLEC-2 is podopla-
nin, which we show is highly expressed in the lung on multiple
cell types and upregulated on leucocytes during inflammation
in the lung, in line with previously published data (11, 26, 43,
48, 51). We used cre-loxP technology to induce cell-specific
deletion of podoplanin. Mice generated using Aqp5cre or
VAV1cre-induced podoplanin deletion are viable and have no
overt phenotype. In particular we show for the first time that
podoplanin expressed on AECIs is not required for lung de-
velopment. This argues against a major role of AECI-ex-
pressed podoplanin in contributing to the embryonic lethality
observed in constitutive podoplanin knockout mice (50). Fur-
thermore, we observe that use of Aqp5cre has the ability to
reduce expression of the floxed gene in LECs and macrophages
digested from lung tissue. Although this was not reported in the
original description of the Aqp5cre mouse, this may be due to
expression of Aqp5 on endothelium and leucocytes as reported
in other tissues (27, 38). Furthermore, the Aqp5cre was first
described on a 129S6/SvEvTac background. This newly gen-
erated strain is on a C57Bl/6 background, which may account
for the differences observed.
Using our podoplanin-deficient mouse strains, the data pre-
sented here suggest that podoplanin expressed on lung epithe-
lial, endothelial, and tissue leucocytes does not regulate lung
injury or inflammation. However, podoplanin expression on a
distinct hematopoietic cell(s) is protective during LPS-induced
inflammation in the lung. Furthermore, VAV1 podoplanin-
expressing cells limit BAL protein accumulation and alveolar
hemorrhage, as well as maintain lung function, via modulation
of KC and MIP-2 expression. In particular, as the only cell
population with significantly lower podoplanin expression
solely in Pdpnfl/flVAV1cre mice following LPS (Fig. 5C),
loss of podoplanin from BAL CD11bCD11cF4/80 alveo-
lar inflammatory macrophages may play a key role in limiting
endotoxemia-induced inflammation in the lung. This subpop-
ulation of alveolar macrophages has been reported to express
high levels of matrix metalloproteinase (MMP)-12 (9), which
cleaves and inactivates CXC chemokines, including KC and
MIP-2, contributing to the “off” signal during acute inflamma-
tion of the lung (6). Therefore it is interesting to speculate that
regulation by platelet CLEC-2 may modulate MMP-12 release/
activity via direct interaction with podoplanin on these inflam-
matory alveolar macrophages. This possible mechanism is
summarized in Fig. 8.
Differences between Pdpnfl/flVAV1cre and CLEC-2-defi-
cient animals were also observed. Most notably, the lack of
increased BAL neutrophilia and conversely an increase in BAL
RBC accumulation in the Pdpnfl/flVAV1cre strain post-IT-
LPS. There is growing evidence that podoplanin may interact
with other proteins, including CCL21 and galectin 8 (4, 25).
This may suggest that in Pdpnfl/flVAV1cre animals both
CLEC-2-dependent and CLEC-2-independent mechanisms are
active, both of which contribute to the phenotype observed
post-IT-LPS. We also cannot rule out the possibility that a
stromal/fibroblast podoplanin-expressing cell contributes to the
phenotype of CLEC-2-deficient mice. Future mechanistic stud-
ies are required to fully understand the role of CLEC-2 and
podoplanin during lung inflammation.
Both cre-loxP strategies we employed to delete CLEC-2
have their limitations: 1) use of tamoxifen-may also delete
CLEC-2 in cells besides platelets, although the use of the
CD11c-cre does not support this; 2) tamoxifen is anti-inflam-
matory; however, parameters from our floxed-only controls of
tamoxifen and nontamoxifen-treated controls are comparable;
and 3) previous reports suggest there are limitations in speci-
ficity using cre-loxP technology; specifically, expression of the
PF4cre has recently been shown in low numbers of nonmega-
karyocytic lineages (47). However, the close correlation of data
generated using both strategies strongly support the validity of
our findings.
A further limitation of this study is the use of only one model
of ARDS, which on its own does not completely reproduce all
the features of the clinical syndrome. The main feature of the
IT-LPS model is alveolar neutrophilia. As a role for platelets in
regulating neutrophil recruitment has already been suggested,
we reasoned that IT-LPS would be the best to initially inves-
tigate the role of platelet-expressed CLEC-2. It will now be
essential to confirm these findings in other mouse models of
ARDS.
In conclusion, our data support the finding that CLEC-2
expressed on platelets is required to limit neutrophil recruit-
ment, which, in turn, limits lung function decline in a mouse
model of ARDS. In addition, expression of the CLEC-2 ligand
podoplanin is required on hematopoietic cells to limit neutro-
phil chemokine expression and consequently arterial oxygen
saturation decline. Therefore we 1) demonstrate that the plate-
let CLEC-2-podoplanin signaling axis is a novel regulator of
lung inflammation in mouse 2), emphasize the complex role
platelets play during mouse ARDS, and 3) identify the platelet
CLEC-2-podoplanin pathway as a possible novel target for
therapeutic intervention in patients at risk of developing
ARDS.
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